Updated Priorities for Cerebroprotection Trials

A STAIR XIII (Stroke Treatment Academic Industry Roundtable) workshop was held to discuss aspects of trials likely to have the greatest impact on detecting meaningful treatment effects of cerebroprotection in acute stroke. Intended goals for hyperacute protection should be focused on preserving penumbral tissue and delaying infarct core growth to augment the impact of reperfusion therapies. Infarct volume is a biologically and clinically meaningful surrogate imaging marker to assess the treatment effects of cerebroprotection. Lastly, clinical outcome measures for cerebroprotection should include domain-specific and patient-centered outcomes to detect clinically meaningful changes across multiple functional domains.

Authors

Institutions

Publication Details

Journal
Stroke
Published
2025-11-20
DOI
https://doi.org/10.1161/strokeaha.125.052147
Citations
3
Primary Topic
Acute Ischemic Stroke Management
Type
article
Field-Weighted Citation Impact
4.06
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Updated Priorities for Cerebroprotection Trials

Urs Fischer, Johannes Boltze, Theodore E. Liston, Carolina M. Maier et al.
3 citations
Stroke
Acute Ischemic Stroke Management
4.06
article

Updated Priorities for Cerebroprotection Trials

Urs Fischer, Johannes Boltze, Theodore E. Liston, Carolina M. Maier, Opeolu Adeoye, David S. Liebeskind, Jocelyn Sutherland, Johanna Maria Ospel, Marc Fisher, Sean I. Savitz, Marcelo Borges Rocha, William S. Korinek, George Harston, Edgar Andres Samaniego, Davide Carone, Bruce C.V. Campbell, Pooja Kumari Khatri, Paul Wechsler, Patrick D. Lyden, Lee H. Schwamm, Liping Liu, Michael D. Hill, Joseph P. Broderick, Gary Houser, Kevin N. Sheth, Supurna Ghosh
article en
3 citations

Abstract

A STAIR XIII (Stroke Treatment Academic Industry Roundtable) workshop was held to discuss aspects of trials likely to have the greatest impact on detecting meaningful treatment effects of cerebroprotection in acute stroke. Intended goals for hyperacute protection should be focused on preserving penumbral tissue and delaying infarct core growth to augment the impact of reperfusion therapies. Infarct volume is a biologically and clinically meaningful surrogate imaging marker to assess the treatment effects of cerebroprotection. Lastly, clinical outcome measures for cerebroprotection should include domain-specific and patient-centered outcomes to detect clinically meaningful changes across multiple functional domains.

StrokeVol. 57(3)
University of Iowa (US), University of California, Los Angeles (US), UCLA Health (US), University of Warwick (GB), The University of Texas Health Science Center (US)
Openalex Percentile: Top 5%
Acute Ischemic Stroke Management
4.06
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.